Specific allergen immunotherapy: time for alternatives?

[1]  R. Puy,et al.  Allergen immunotherapy for asthma. , 2003, The Cochrane database of systematic reviews.

[2]  H. Eichler,et al.  Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  R. Lockey,et al.  Systemic reactions and fatalities associated with allergen immunotherapy. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  L. Cohn.  Food for thought: can immunological tolerance be induced to treat asthma? , 2001, American journal of respiratory cell and molecular biology.

[5]  G. Passalacqua,et al.  Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  C. Caffarelli,et al.  Preseasonal local allergoid immunotherapy to grass pollen in children: a double‐blind, placebo‐controlled, randomized trial , 2000, Allergy.

[7]  H. Link,et al.  Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  J. Lamb,et al.  Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. , 2000, International immunology.

[9]  S. Gangemi,et al.  Sublingual immunotherapy: a double‐blind, placebo‐controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both , 1999, Allergy.

[10]  G. Canonica,et al.  Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. , 1999, The Journal of allergy and clinical immunology.

[11]  A. Pradalier,et al.  Sublingual‐swallow immunotherapy (SLIT) with a standardized five‐grass‐pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis , 1999, Allergy.

[12]  D. Caillaud,et al.  Sublingual‐swallow immunotherapy (SLIT) in patients with asthma due to house‐dust mites: a double‐blind, placebo‐controlled study , 1999, Allergy.

[13]  P. Papageorgiou,et al.  Double‐blind, placebo‐controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization , 1998, Allergy.

[14]  J. Bousquet,et al.  Clinical efficacy of sublingual‐swallow immunotherapy: a double‐blind, olacebo‐controlled trial of a standardized five‐grass‐pollen extract in rhinitis , 1998, Allergy.

[15]  G. Canonica,et al.  Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis , 1998, The Lancet.

[16]  G. Canonica,et al.  Long‐term follow‐up of nasal immunotherapy to Parietaria: clinical and local immunological effects , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[18]  E. Iemoli,et al.  Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  E. Novembre,et al.  Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: a controlled study. , 1996, Journal of investigational allergology & clinical immunology.

[20]  E. Savi,et al.  Rush sublingual immunotherapy in Parietaria allergic patients. , 1996, Allergologia et immunopathologia.

[21]  G. Canonica,et al.  Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. , 1995, American journal of respiratory and critical care medicine.

[22]  B. Björkstén,et al.  Local immunotherapy is not documented for clinical use , 1994, Allergy.

[23]  A. Sabbah,et al.  A double‐blind, placebo‐controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract , 1994, Allergy.

[24]  G. Passalacqua,et al.  A three‐year double‐blind placebo‐controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  E. Pastorello,et al.  A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria Judaica in patients with Parietaria hay fever , 1994, Allergy.

[26]  R. O’Hehir,et al.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.

[27]  G. Senna,et al.  Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. , 1993, The Journal of allergy and clinical immunology.

[28]  V. Brusasco,et al.  Local immunotherapy with Dermatophagoides extract in asthma. , 1991, The Journal of allergy and clinical immunology.

[29]  J. Douglass,et al.  Allergen immunotherapy: Current and new therapeutic strategies , 2002 .

[30]  B. Fazekas de St. Groth,et al.  The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. , 1998, Immunology today.

[31]  [WHO position paper. "Allergen immunotherapy: therapeutic vaccines for allergic diseases"]. , 1998, Arerugi = [Allergy].

[32]  G. Hordijk,et al.  Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. , 1998, Allergologia et immunopathologia.

[33]  G. Senna,et al.  Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. , 1996, The Journal of allergy and clinical immunology.

[34]  S. Voltolini,et al.  Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. , 1995, Journal of investigational allergology & clinical immunology.